Liposomal delivery of mitoxantrone and a cholesteryl indoximod prodrug provides effective chemo-immunotherapy in multiple solid tumors
We developed a custom-designed liposome carrier for codelivery of a potent immunogenic
cell death (ICD) stimulus plus an inhibitor of the indoleamine 2, 3-dioxygenase (IDO-1) …
cell death (ICD) stimulus plus an inhibitor of the indoleamine 2, 3-dioxygenase (IDO-1) …
Utilization of macrocyclic peptides to target protein-protein interactions in cancer
J Yang, Q Zhu, Y Wu, X Qu, H Liu, B Jiang, D Ge… - Frontiers in …, 2022 - frontiersin.org
Protein-protein interactions (PPIs) play vital roles in normal cellular processes. Dysregulated
PPIs are involved in the process of various diseases, including cancer. Thus, these PPIs …
PPIs are involved in the process of various diseases, including cancer. Thus, these PPIs …
[HTML][HTML] Abrogation of USP7 is an alternative strategy to downregulate PD-L1 and sensitize gastric cancer cells to T cells killing
Z Wang, W Kang, O Li, F Qi, J Wang, Y You… - … pharmaceutica sinica B, 2021 - Elsevier
Targeting immune checkpoints such as programmed cell death protein 1 (PD-1) and
programmed death ligand-1 (PD-L1) have been approved for treating melanoma, gastric …
programmed death ligand-1 (PD-L1) have been approved for treating melanoma, gastric …
OX40L-armed oncolytic virus boosts T-cell response and remodels tumor microenvironment for pancreatic cancer treatment
S Liu, F Li, Q Ma, M Du, H Wang, Y Zhu, L Deng… - …, 2023 - pmc.ncbi.nlm.nih.gov
Rationale: The resistance of pancreatic ductal adenocarcinoma (PDAC) to immunotherapies
is caused by the immunosuppressive tumor microenvironment (TME) and dense …
is caused by the immunosuppressive tumor microenvironment (TME) and dense …
Neutrophil–lymphocyte ratio (NLR) predicted prognosis for advanced non-small-cell lung cancer (NSCLC) patients who received immune checkpoint blockade (ICB)
F Ren, T Zhao, B Liu, L Pan - OncoTargets and therapy, 2019 - Taylor & Francis
Purpose The aim of this study was to identify the prognostic value of blood neutrophil–
lymphocyte ratio (NLR) in patients with advanced non-small-cell lung cancer (NSCLC) who …
lymphocyte ratio (NLR) in patients with advanced non-small-cell lung cancer (NSCLC) who …
OX40 agonists for cancer treatment: a patent review
J Cebada, M Perez-Santos, C Bandala… - Expert Opinion on …, 2021 - Taylor & Francis
Introduction OX40 is an immune checkpoint in cancer and its presence in cancer is a good
prognosis, making it a highly relevant target for the development of new immunotherapies …
prognosis, making it a highly relevant target for the development of new immunotherapies …
Design, synthesis, and biological evaluation of linear aliphatic amine-linked triaryl derivatives as potent small-molecule inhibitors of the programmed cell death-1 …
J Guo, L Luo, Z Wang, N Hu, W Wang… - Journal of Medicinal …, 2020 - ACS Publications
A series of novel linear aliphatic amine-linked triaryl derivatives as inhibitors of PD-1/PD-L1
were designed, synthesized, and evaluated in vitro and in vivo. In this chemical series …
were designed, synthesized, and evaluated in vitro and in vivo. In this chemical series …
Interfering with the tumor–immune interface: making way for triazine-based small molecules as novel PD-L1 inhibitors
P Russomanno, G Assoni, J Amato… - Journal of medicinal …, 2021 - ACS Publications
The inhibition of the PD-1/PD-L1 axis by monoclonal antibodies has achieved remarkable
success in treating a growing number of cancers. However, a novel class of small organic …
success in treating a growing number of cancers. However, a novel class of small organic …
[HTML][HTML] YPD-30, a prodrug of YPD-29B, is an oral small-molecule inhibitor targeting PD-L1 for the treatment of human cancer
F Lai, M Ji, L Huang, Y Wang, N Xue, T Du… - … Pharmaceutica Sinica B, 2022 - Elsevier
Abstract PD-1 and PD-L1 antibodies have brought about extraordinary clinical benefits for
cancer patients, and their indications are expanding incessantly. Currently, most PD-1/PD …
cancer patients, and their indications are expanding incessantly. Currently, most PD-1/PD …
Inhibition of PD-L1-mediated tumor-promoting signaling is involved in the anti-cancer activity of β-tocotrienol
Z Sun, S Yin, C Zhao, L Fan, H Hu - Biochemical and biophysical research …, 2022 - Elsevier
Abstract Programmed death-ligand 1 (PD-L1), a critical immune checkpoint ligand, is
commonly overexpressed on the surface of many tumor types including lung and prostate …
commonly overexpressed on the surface of many tumor types including lung and prostate …